Sandoz sues Amgen in US for blocking biosimilar rivals
MLex Summary: Biotech giant Amgen is facing an antitrust lawsuit in the US from Swiss generic and biosimilar specialist Sandoz, which accuses it of “extending and entrenching the dominant market position...To view the full article, register now.
Already a subscriber? Click here to view full article